



Thank you to everyone who made
this conference the best one yet!

The 2015 Conference Recap

The Annual Prostate Cancer Conference is a unique event where patients gather and learn about the latest advancements in the prostate cancer world. Patients also have access to general prostate cancer information and are presented with various resources. These include leading doctors, fellow patients, support groups, and industry partners.

Thanks to your support, the 2015 Prostate Cancer Conference was our best one yet! Our speakers delivered phenomenal presentations, and patients were intently engaged in the support groups and various breakout sessions. Overall, we believe it was the best experience we have created for our attendees so far. Over 800 attended; patients, caregivers, support groups, industry partners, and doctors came from across the nation (and some internationally!) to be a part of the 2015 Conference experience. Everyone who attended synergistically created a spirit of collaboration and hope.

The conference embodies our belief that the best care, and empowerment come about when there is a free flow of conversation between doctors and patients. At the conference, we take this further by bringing in support groups and industry partners, who can provide unique information which cannot be found elsewhere. To ensure that the information was understandable to patients, Mark Moyad, MD, the conference moderator posed poignant questions to the speakers during the second half of their presentations. This collaboration was especially pronounced during the smaller, more intimate Q&A sessions that followed each speakers' presentation.

**2015 PROSTATE
CANCER
CONFERENCE**



Moyad and Scholz at the Conference

In addition to our regular presentations, Q&A sessions, breakout sessions, and support groups, we added a *New Technologies Workshop* to our lineup. A big part of the conference, and one reason that brings people back every

“The conference embodies our belief that the best care, hope and empowerment come about when there is a free flow of conversation, and interaction between doctors and patients.”

year, is that we present the newest developments and technologies every year. To build on this, on Friday afternoon, Mark Scholz, MD, moderated as industry partners presented information about the new genomic tests available. After the individual presentations, the presenters answered questions from the audience.

Subsequently, members of our helpline staff answered questions in a panel format. The subject matter primarily focused on the doctor patient relationship and covered key concepts about getting the most from your interactions with your doctor. After this, patients gathered in the Champions bar next door to rub elbows with the other attendees.

On Saturday, **Tomasz Beer, MD**, from the University of Oregon, provided an update on the two new hormonal agents, Zytiga and Xtandi. He reviewed the present thinking on treatment sequencing for men who become resistant to Lupron.

Charles Drake, MD, from Johns Hopkins, a preeminent expert on immune therapy for prostate cancer, presented exciting data on how many of the new immune drugs work synergistically when given in combination.

Peter Grimm, DO, often called “The Father of Seed Implant Therapy,” delivered a candid overview of radiation therapy, emphasizing the improved cure rates

and reduced toxicity of seed implant therapy. He also spoke on how increased financial incentives to do IMRT, Proton therapy and SBRT, can distort the decision making process.

Daniel Margolis, MD, an expert on prostate imaging from UCLA, presented information on 3-Tesla, multiparametric MRI's capability as a substitute for random needle biopsy in men with elevated PSA who have never been previously diagnosed with prostate cancer.

John Mulhall, MD, the preeminent expert on sexuality and prostate cancer from Memorial Sloan Kettering, emphasized mindfulness in the selection of treatment. He stressed that it is better to minimize damage by selecting the least toxic form of prostate cancer treatment than trying to fix an already established problem.

Fabio Almeida, MD, spoke on behalf of Dr. William Oh about a form of injectable radiation called Xofigo. He presented a notable case of a patient from his clinic who received Xofigo and experienced almost total remission of his bone disease.

Matthew Cooperberg, MD, from UCSF spoke on several important themes. He presented new findings that show that the pool of men who can consider active surveillance is expanding. Previously only men in the low-risk category were considered good candidates for active



Advanced Cancer Support Group at the 2015 Conference with Malecare's Joel Nowak, the recipient of the 2014 Harry Pinchot Award

surveillance. Presently, even men with favorable types of intermediate-risk disease can consider active surveillance.

Final Thoughts:

By connecting with other patients, doctors, support groups, and industry partners, attendees were able to enjoy a full featured collaborative learning experience at the 2015 Conference. We look forward to seeing you at a future PCRI event. ■

DVDs which include all the presentations and Q&A sessions from the 2015 Conference, will be available soon. For more information, visit www.pcri.org.

Program Update



New Technologies Workshop



Helpline Panel



*2015 Harry Pinchot Awardee Russ Thomas
from Prostate Forum of Orange County*



Dr. Margolis During his Q&A Session



*Saturday Evening Gala Dinner
with the Steve McCann Jazz Band*



Sunday Ask The Experts Breakout Sessions